Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALE.P03 in CLDN1-positive advanced or metastatic solid tumors
2025-521441-24-00Phase 2Authorised
- Sponsor
- Alentis Therapeutics
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of ALE.P03 in colorectal cancer (CRC), intrahepatic cholangiocarcinoma (ICC), Pulmonary squamous cell carcinoma and 2 more (2 arms), sponsored by Alentis Therapeutics. Primary endpoints: Phase 1: Incidence of DLTs, Phase 1: Incidence and severity of AEs and SAEs and 6 more. Planned start Nov 2025; status: authorised.
02
Drugs
ALE.P03
03
Conditions
colorectal cancer (CRC)intrahepatic cholangiocarcinoma (ICC)Pulmonary squamous cell carcinomatransitional cell carcinoma (TCC)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2025-521441-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521441-24-00.